The US Food and Drug Administration has received largely negative reviews from industry for its proposal to require fixed-quantity unit-of-use blister packaging of certain opioid products, with many groups calling for the agency to conduct a study before moving forward.
The Association for Accessible Medicines urged FDA to examine the economics of blister packaging for manufacturers under the existing supply...




